Julia Willingham, MD
Urology · Fort Worth, TXNPI 1154765147
Payments from drug & device makers
Across 222 payments — averaging $39.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Axonics, Inc.$962
- Teleflex LLC$770
- Calyxo, Inc.$573
- Astellas Pharma US Inc$372
- Olympus America Inc.$351
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$2583%
- Travel & lodging$1,90822%
- Food & beverage$6,65075%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 24 | $2,653 |
| Axonics, Inc. | 26 | $962 |
| Teleflex LLC | 12 | $770 |
| Calyxo, Inc. | 6 | $573 |
| Astellas Pharma US Inc | 16 | $372 |
| Olympus America Inc. | 11 | $351 |
| AbbVie(2 entities) | 18 | $345 |
| Bluewind Medical | 5 | $333 |
| Sumitomo Pharma America, Inc. | 15 | $265 |
| Procept Biorobotics Corporation | 4 | $242 |
| 180 Medical, Inc. | 9 | $236 |
| Urogen Pharma, Inc. | 6 | $227 |
| Valencia Technologies Corporation | 6 | $177 |
| Coloplast | 6 | $123 |
| Ferring Pharmaceuticals Inc. | 4 | $106 |
| Endo Pharmaceuticals Inc. | 6 | $93 |
| Endo USA, Inc. | 4 | $88 |
| Merck | 3 | $77 |
| Myovant Sciences Inc. | 4 | $75 |
| Neotract Inc. | 3 | $66 |
| Johnson & Johnson | 4 | $65 |
| Medtronic(2 entities) | 3 | $61 |
| Immunitybio, Inc. | 2 | $55 |
| Tolmar, Inc. | 3 | $49 |
| Bioprotect Medical, Inc. | 2 | $47 |
| Travere Therapeutics, Inc. | 2 | $46 |
| Antares Pharma, Inc. | 3 | $41 |
| Laborie Medical Technologies Corp. | 1 | $39 |
| Sanofi | 2 | $37 |
| Blue Earth Diagnostics | 2 | $34 |
| Cook Medical LLC | 1 | $29 |
| Telix Pharmaceuticals | 1 | $27 |
| Bayer | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Ambu Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Civco Medical Instruments | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $19 |
| Urovant Sciences Inc | 1 | $15 |
| Mission Pharmacal Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Moses 550 D\F\L$1,729
- Axonics$559
- CVAC Aspiration System$366
- UroLift System$319
- Bulkamid$251
- GENERAL BPH$201
- AquaBeam Robotic System$174
- REVI$159
- iTIND System$138
- XTANDI$125
- GENERAL - THERAPIES$123
- rezum Generator$106
- JELMYTO$104
- SpaceOAR VUE System - 10mL$100
How this compares
$8,816 in reported general payments places this provider in the 70th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 379 | $255,990 |
| GemtesaVibegron | 66 | $52,471 |
| Mirabegron ErMirabegron | 45 | $23,109 |
| Estradiol | 280 | $19,246 |
| Trospium Chloride | 93 | $8,824 |
| Solifenacin Succinate | 84 | $5,630 |
| Methenamine Hippurate | 26 | $2,169 |
| Cefaclor | 26 | $1,928 |
| Tamsulosin Hcl | 143 | $1,780 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 45 | $1,605 |
| Bethanechol Chloride | 36 | $1,569 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,534 |
| Cephalexin | 145 | $1,458 |
| Oxybutynin Chloride | 69 | $1,129 |
| Ciprofloxacin Hcl | 222 | $886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $372 | $255,990379 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $265 | $52,47166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 urology providers in Texas.
Other urology in Fort Worth
- Michael ColliniFort Worth$183K
- Zvi SchiffmanHouston$17.8M
- Jose de la CerdaSan Antonio$9M
- Daniel SaltzsteinSan Antonio$5.8M
- Jose KaramHouston$5.7M
- Daniel ZainfeldSan Antonio$4.7M
- Brian MazzarellaLakeway$4.5M
- Andrew von EschenbachMontgomery$3.2M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.